{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T05:33:08Z","timestamp":1737005588102,"version":"3.33.0"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1721","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain and altered bowel habits, often accompanied by bloating.1-4 IBS is classified by its predominant bowel symptom: constipation (IBS-C), diarrhea (IBS-D), mixed type (IBS-M), or unclassified (IBS-U).1 Since the exact cause of IBS is unknown, the goal of treatment is symptom control.<\/jats:p>","DOI":"10.58347\/tml.2025.1721a","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T17:16:46Z","timestamp":1736961406000},"page":"17-24","source":"Crossref","is-referenced-by-count":0,"title":["Drugs for Irritable Bowel Syndrome"],"prefix":"10.58347","volume":"67","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2025,2,3]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T17:16:47Z","timestamp":1736961407000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1721a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":0,"journal-issue":{"issue":"1721","published-online":{"date-parts":[[2025,2,3]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2025.1721a","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]}}}